Increased aortic atherosclerotic plaque development in female apolipoprotein E-null mice is associated with elevated thromboxane A2 and decreased prostacyclin production

Journal of Physiology and Pharmacology

Volumn 61, Issue 3, 2010, Pages 309-316

  Smith, D D ^a   Tan, X ^a   Tawfik, O ^a   Milne, G ^b   Stechschulte, D J ^a   Dileepan, K N ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Estrogen; Gender difference; High fat diet; Prostaglandin i2; Thromboxane A2

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; ESTRADIOL; PROSTACYCLIN; THROMBOXANE A2; LIPID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ARCH; AORTA ATHEROSCLEROSIS; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CELL COUNT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MAST CELL; MOUSE; NONHUMAN; QUANTITATIVE ANALYSIS; RISK FACTOR; SEX DIFFERENCE; T LYMPHOCYTE; URINALYSIS; ANIMAL; AORTA; ATHEROSCLEROSIS; BLOOD; BLOOD ANALYSIS; DISEASE MODEL; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; SEXUAL DEVELOPMENT;

ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD CHEMICAL ANALYSIS; DISEASE MODELS, ANIMAL; EPOPROSTENOL; ESTRADIOL; FEMALE; LIPIDS; MACROPHAGES; MALE; MAST CELLS; MICE; MICE, KNOCKOUT; SEX CHARACTERISTICS; T-LYMPHOCYTES; THROMBOXANE A2;

EID: 77957089193     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Davies MJ. Apoptosis in cardiovascular disease. Heart 1997; 77: 498-501.
2. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
3. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell 2001; 104: 503-516.
4. Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis.Circ Res 2002; 91: 281-291.
5. Grainger DJ, Metcalfe JC. A pivotal role for TGF-beta in atherogenesis? Biol Rev Camb Philos Soc 1995; 70: 571-596.
6. Reckless J, Metcalfe JC, Grainger DJ. Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice. Circulation 1997; 95: 1542-1548.
7. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. BMJ 1991; 303: 435-437.
8. Rutqvist LE. Long-term toxicity of tamoxifen. Recent Results Cancer Res 1993; 127: 257-266.
9. Dewar JA, Horobin JM, Preece PE, Tavendale R, Tunstall-Pedoe H, Wood RA. Long term effects of tamoxifen on blood lipid values in breast cancer. BMJ 1992; 305: 225-226.
10. Love RR, Newcomb PA, Wiebe DA, et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 1990; 82: 1327-1332.
11. The Writing Group of the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen /Progestin Interventions (PEPI) Trial. JAMA 1995; 273: 199-208.
12. FitzGerald GA, Smith B, Pedersen AK, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 1984; 310:1065-1068.
13. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2 -dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102: 840-845.
14. Turk JR. Protocol for macroscopic sudan IV staining of arteries for fatty streaks. MU Vasc Cell Biol. http://exercisevascularcells.org/SOP_CoreB/54.htm: 2002; 1-2.
15. Kobayashi T, Tahara Y, Matsumoto M, et al. Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 2004; 114: 784-794.
16. Hodgin JB, Maeda N. Minireview: Estrogen and mouse models of atherosclerosis. Endocrinology 2002; 143: 4495-4501.
17. von Dehn G, von Dehn O, Volker W, et al. Atherosclerosis in apolipoprotein E-deficient mice is decreased by the suppression of endogenous sex hormones. Horm Metab Res 2001; 33: 110-114.
18. Badimon L. Atherosclerosis and thrombosis: lessons from animal models. Thromb Haemost 2001; 86: 356-365.
19. Belton OA, Duffy A, Toomey S, Fitzgerald DJ. Cyclooxygenase isoforms and platelet vessel wallinteractions in the apolipoprotein E knockout mouse model of atherosclerosis. Circulation 2003; 108:3017-3023.
20. Olszanecki R, Jawien J, Gajda M, et al. Effect of curcumin on atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol 2005; 46: 627-635.
21. Meir KS, Leitersdorf E. Atherosclerosis in the apolipoprotein-E-deficient mouse: a decade of progress. Arterioscler Thromb Vasc Biol 2004; 24: 1006-1014.
22. Ma Z, Choudhury A, Kang SA, Monestier M, Cohen PL, Eisenberg RA. Accelerated atherosclerosis in ApoE deficient lupus mouse models. Clin Immunol 2008; 127: 168-175.
23. Paszty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest 1994; 94: 899-903.
24. Petrovan RJ, Kaplan CD, Reisfeld RA, Curtiss LK. DNA vaccination against VEGF receptor 2 reduces atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2007; 27: 1095-1100.
25. Maeda N, Johnson L, Kim S, Hagaman J, Friedman M, Reddick R. Anatomical differences and atherosclerosis in apolipoprotein E-deficient mice with 129/SvEv and C57BL/6 genetic backgrounds. Atherosclerosis 2007; 195: 75-82.
26. Pratico D, Cyrus T, Li H, FitzGerald GA. Endogenous biosynthesis of thromboxane and protacyclin in 2 distinct murine models of atherosclerosis. Blood 2000; 96: 3823-3826.
27. Jawien J, Gajda M, Olszanecki R, Korbut R. BAY x 1005 attenuates atherosclerosis in apoE/LDLR-double knockoutmice. J Physiol Pharmacol 2007; 58: 583-588.
28. Jawien J, Gajda M, Wolkow P, Zuranska J, Olszanecki R, Korbut R. The effect of montelukast on atherogenesis in apoE/LDLR-double knockout mice. J Physiol Pharmacol 2008; 59: 633-639.
29. Babaev VR, Ding L, Reese J, et al. Cyclooxygenase-1 deficiency in bone marrow cells increases early atherosclerosis in apolipoprotein E- and low-density lipoprotein receptor-null mice. Circulation 2006; 113: 108-117.
30. Yan Q, Yang X, Cantone A, Giebisch G, Hebert S, Wang T. Female ROMK null mice manifest more severe Bartter II phenotype on renal function and higher PGE2 production. Am J Physiol Reg Integr Comp Phys 2008; 295: R997-R1004.
31. Egan KM, Wang M, Lucitt MB, et al. Plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 2005; 111: 334-342.
32. Dileepan KN, Johnston TP, Li Y, Tawfik O, Stechschulte DJ. Deranged aortic intima-media thickness, plasma triglycerides and granulopoiesis in SI/SId mice. Med Inflamm 2004; 13: 335-341.
33. Bourassa P-AK, Milos PM, Baynor BJ, Breslow JL, Aiello RJ. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 1996; 93: 10022-10027.
34. Villablanca A, Lubahn D, Shelby L, Lloyd K, Barthold S. Susceptibility to early atherosclerosis in male mice is mediated by estrogen receptor α. Arterioscler Thromb Vasc Biol 2004; 24: 1055-1061.
35. Ishida T, Choi SY, Kundu RK, et al. Endothelial lipase modulates susceptibility to atherosclerosis in apolipoprotein-E-deficient mice. J Biol Chem 2004; 279: 45085-45092.
36. Ishida T, Choi SY, Kundu RK, et al. Endothelial lipase is a major determinant of HDL level. J Clin Invest 2003; 111: 347-355.
37. Ma K, Cilingiroglu M, Otvos JD, Ballantyne CM, Marian AJ, Chan L. Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. Proc Natl Acad Sci USA 2003; 100: 2748-2753.
38. Jin W, Millar JS, Broedl U, Glick JM, Rader DJ. Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. J Clin Invest 2003; 111: 357-362.
39. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995; 15: 551-561.
40. Marsh MM, Walker VR, Curtiss LK, Banka CL. Protection against atherosclerosis by estrogen is independent of plasma cholesterol levels in LDL receptor-deficient mice. J Lip Res 1999; 40: 893-900.
41. Nathan L, Shi W, Dinh H, et al. Testosterone inhibits early atherogenesis by conversion to extradiol: critical role of aromatase. Proc Natl Acad Sci USA 2001; 98: 3589-3593.
42. Li M, Kuo L, Stallone JN. Estrogen potentiates constrictor prostanoid function in female rat aorta by up regulation of cyclooxygenase-2 and thromboxane pathway expression. Am J Physiol Heart Circ Physiol 2008; 294: H2444-H2455.
43. Marttunen MB, Pyrhonen S, Tiitinen AE, Viinikka LU, Ylikorkala O. Effect of antiestrogen regimen on prostacyclin and thromboxane A2 in postmenopausal patients with breast
44. cancer: evidence of significance of hypertension, smoking or previous use of estrogen therapy. Prostaglandins 1996; 52: 317-326.
45. VanderLaan PA, Reardon CA. Thematic review series: The immune system and atherogenesis. The unusual suspects: an overview of the minor leukocyte populations in atherosclerosis. J Lip Res 2005; 46: 829-838.
46. Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 2008; 79: 360-376.
47. Sun J, Sukhova GK, Wolters PJ, et al. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nature Med 2007; 13: 719-724.
48. Caligiuri G, Nicoletti A, Zhou X, Tornberg I, Hansson GK. Effects of sex and age on atherosclerosis and autoimmunity in apoE-deficient mice. Atherosclerosis 1999; 145: 301-308.
49. Jakubowski H. The pathophysiological hypothesis of homocysteine thiolactone-mediated vascular disease. J Physiol Pharmacol 2008; 59:(Suppl 9): 155-167.
50. Kus K, Gajda M, Pyka-Fosciak G, et al. The effect of nebivolol on atherogenesis in apoE-knockout mice. J Physiol Pharmacol 2009; 60: 163-165.
51. Dejeans N, Auclair S, Chauvet S, Milenkovic D, Mazur A. Transcriptomic analysis of aorta from a short- term high-fat diet fed mouse reveals changes in the expression of vessel structure genes. J Physiol Pharmacol 2009; 60: 37-45.
52. Fata JE, Chaudhary V, Khokha R. Cellular turnover in the mammary gland is correlated with systemic levels of progesterone and not 17beta-estradiol during the estrous cycle. Biol Reprod 2001; 65: 680-688.
53. Hirschfield GM, Gallimore JR, Kahan MC, et al. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA. 2005; 102: 8309-8314.